4 hours Ago By Defense World Staff
Raymond James Financial Inc. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund bought 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Raymond James Financial Inc. owned 0.
06% of PTC Therapeutics as of its most recent SEC filing. Other institutional investors have also bought and sold shares of the company. Vontobel Holding Ltd.
acquired a new position in shares of PTC Therapeutics in the 4th quarter valued at about $521,000. Natixis Advisors LLC acquired a new position in PTC Therapeutics in the fourth quarter valued at approximately $544,000. Proficio Capital Partners LLC bought a new position in shares of PTC Therapeutics during the 4th quarter worth approximately $758,000.
American Century Companies Inc. boosted its holdings in shares of PTC Therapeutics by 66.8% during the 4th quarter.
American Century Companies Inc. now owns 60,150 shares of the biopharmaceutical company’s stock worth $2,715,000 after buying an additional 24,090 shares in the last quarter. Finally, GC Wealth Management RIA LLC acquired a new stake in shares of PTC Therapeutics during the 4th quarter worth approximately $363,000.
PTC Therapeutics Stock PerformanceShares of PTCT stock opened at $49.84 on Thursday. The company has a market capitalization of $3.
93 billion, a price-to-earnings ratio of -8.39 and a beta of 0.58.
PTC Therapeutics, Inc. has a 52-week low of $28.72 and a 52-week high of $58.
38. The company has a 50-day simple moving average of $50.02 and a two-hundred day simple moving average of $46.
74. Analyst Ratings ChangesSeveral brokerages recently issued reports on PTCT. Cantor Fitzgerald increased their target price on shares of PTC Therapeutics from $76.
00 to $113.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Bank of America raised shares of PTC Therapeutics from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $41.
00 to $55.00 in a research report on Tuesday, March 11th. JPMorgan Chase & Co.
decreased their target price on PTC Therapeutics from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, March 31st.
Scotiabank initiated coverage on PTC Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $55.00 price objective for the company.
Finally, Royal Bank of Canada restated an “outperform” rating and set a $65.00 price objective on shares of PTC Therapeutics in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock.
According to MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $63.92.View Our Latest Stock Report on PTC TherapeuticsInsider ActivityIn related news, Director Allan Steven Jacobson sold 1,230 shares of the firm’s stock in a transaction dated Tuesday, March 4th.
The shares were sold at an average price of $51.52, for a total transaction of $63,369.60.
Following the completion of the sale, the director now owns 19,118 shares in the company, valued at approximately $984,959.36. This trade represents a 6.
04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stephanie Okey sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 13th.
The shares were sold at an average price of $54.00, for a total transaction of $270,000.00.
Following the completion of the transaction, the director now owns 8,867 shares in the company, valued at approximately $478,818. The trade was a 36.06 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Insiders sold a total of 32,305 shares of company stock valued at $1,682,755 over the last three months. Corporate insiders own 5.
50% of the company’s stock. PTC Therapeutics Profile (Free Report)PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
See AlsoFive stocks we like better than PTC TherapeuticsWhat Do S&P 500 Stocks Tell Investors About the Market? Why D-Wave’s Project With Davidson Is a Game-Changer For QuantumTechnology Stocks Explained: Here’s What to Know About TechHims & Hers Stock Soars on Novo Nordisk CollaborationMost Volatile Stocks, What Investors Need to KnowAmazon’s Earnings Will Make or Break the Stock’s Comeback.
